Subscribe Sign In

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.

https://www.wsj.com/articles/ftc-rejects-illuminas-7-billion-deal-for-cancer-test-developer-grail-50d2c05c

FTC Rejects Illumina’s $7 Billion Deal for Cancer-Test Developer Grail

The agency said the combination would hurt competition for cancer-detection tests while raising prices

San Diego-based Illumina was ordered to unwind its already completed acquisition.Photo: MIKE BLAKE/REUTERS

By Jonathan D. Rockoff

and Peter Loftus

Updated April 3, 2023 10:44 am ET

The Federal Trade Commission rejected Illumina Inc.’s $7 billion deal for cancer-test developer Grail Inc., saying that going ahead would hurt competition in one of the new frontiers of diagnostic medicine.

The FTC on Monday ordered Illumina to unwind the proposed merger, reversing an administrative law judge’s ruling that supported the big medical testing company.

What's News

Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Continue reading your article with
a WSJ subscription

Already a subscriber? Sign In

Sponsored Offers

Target:
Target Promo Code: 20% off Entire Order
Vitacost:
Vitacost Promo Code: 20% OFF all Rainbow Light products
Walmart:
Walmart Egg Hunt Sale: Up to 80% off all categories
Groupon:
Groupon Promo Code - 30% Off
adidas:
adiClub Members: Extra 33% Off + Free Shipping
Nike:
60% off running shoes and apparel at Nike without a promo code